ArticleThe Journal of experimental medicine2017
Immune checkpoints on innate lymphoid cells.
Article in The Journal of experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Intestinal CXCR6Immunity · 2024Article
- Assessing the Impact of Persistent HIV Infection on Innate Lymphoid Cells Using In Vitro Models.ImmunoHorizons · 2023Article
- Btn2a2 Regulates ILC2-T Cell Cross Talk in Type 2 Immune Responses.Frontiers in immunology · 2022Article
- Innate lymphoid cells and cancer: Role in tumor progression and inhibition.European journal of immunology · 2021Review
- PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects.International journal of molecular sciences · 2021Review
- Healthy and Patient Type 2 Innate Lymphoid Cells are Differently Affected by in vitro Culture Conditions.Journal of asthma and allergy · 2021Article
- Review
- Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28.British journal of pharmacology · 2020Review
- Single-cell analysis of RORα tracer mouse lung reveals ILC progenitors and effector ILC2 subsets.The Journal of experimental medicine · 2020Article
- Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors.Frontiers in oncology · 2020Review
- CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.Blood advances · 2019Article
- Functions of Group 2 Innate Lymphoid Cells in Tumor Microenvironment.Frontiers in immunology · 2019Review
- PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.Frontiers in immunology · 2019Review
- CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.Human vaccines & immunotherapeutics · 2017Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of JEM, Taylor et al. (https://doi.org/10.1084/jem.20161653) describe PD-1 as a critical negative regulator of group 2 innate lymphoid cells (ILC-2s). PD-1 intrinsically controls proliferation and cytokine production of both mouse and human ILC-2s. PD-1 signaling inhibits STAT5 phosphorylation and the removal of this brake by knocking down PD-1 expression or by using anti-PD-1 blocking antibodies, translated in vivo into better clearance of helminth worm infection in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.